Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$788.76 USD

788.76
1,497,572

+12.38 (1.60%)

Updated Nov 7, 2024 11:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis

Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.

Kinjel Shah headshot

5 Large Drug Stocks to Watch From a Thriving Industry

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.

Pfizer's (PFE) Oral Diabetes Drug Aids in Weight Loss, Stock Up

Data from a phase II study published in JAMA showed that Pfizer's (PFE) danuglipron reduces glycated hemoglobin and fasting plasma glucose (at all doses) and body weight (at the highest doses) at week 16.

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Eli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key to Growth

Lilly (LLY) expects to launch four new medicines by 2023 end, of which Mounjaro for type II diabetes and cancer drug Jaypirca have already been launched.

Bryan Hayes headshot

Bearish Headwinds Have Evolved to Bullish Tailwinds: This Industry Soars

The headline inflation figure rose at the slowest rate in more than two years.

Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat

Nektar's (NKTR) Q1 loss is narrower than expected while revenues beat estimates.

The Zacks Analyst Blog Highlights Eli Lilly, Verizon Communications, United Parcel Service, Advanced Micro Devices and The Cigna Group

Eli Lilly, Verizon Communications, United Parcel Service, Advanced Micro Devices and The Cigna Group are part of the Zacks Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Eli Lilly, Verizon Communications & United Parcel Service

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Verizon Communications Inc. (VZ) and United Parcel Service, Inc. (UPS).

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Sheraz Mian headshot

Top Research Reports for Berkshire Hathaway, Tesla & JPMorgan Chase

Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Tesla, Inc. (TSLA) and JPMorgan Chase & Co. (JPM).

SNY or LLY: Which Is the Better Value Stock Right Now?

SNY vs. LLY: Which Stock Is the Better Value Option?

Incyte (INCY) Q1 Earnings Miss Estimates, Revenues Up Y/Y

Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.

ImmunoGen (IMGN) Q1 Earnings Beat, Elahere Uptake Encouraging

ImmunoGen (IMGN) reports impressive Q1 earnings results on strong adoption of sole-marketed drug Elahere. The company raises financial guidance for 2023. Post the news, shares moved up 25%.

Kinjel Shah headshot

Pharma Stock Roundup: MRK & Others Post Q1 Results, LLY Drug Shines in Obesity Study

Merck (MRK), Eli Lilly (LLY), AstraZeneca (AZN) and others report first-quarter results. J&J (JNJ) provides an update on the IPO of its Consumer Health segment, Kenvue.

Eli Lilly (LLY) Q1 Earnings Miss, Sales Beat, '23 View Raised

Eli Lilly (LLY) reports mixed results for the first quarter of 2023, missing estimates for earnings while beating the same for revenues. Management raises the 2023 outlook.

Lilly (LLY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Eli Lilly (LLY) Q1 Earnings Lag Estimates

Lilly (LLY) delivered earnings and revenue surprises of -6.36% and 2.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

Markets Continue Steady Slide; META, EBAY Beat Q1 Earnings

Except the Nasdaq, which snapped a two-day losing streak and was the only major index in the green all day.

Ahan Chakraborty headshot

Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More

Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.